Tempus xT CDx
Tempus's tumour-and-normal gene panel, FDA-approved in 2023 as a companion test for EGFR antibodies in bowel cancer.
Overview
The FDA approved Tempus xT CDx in 2023 as a 648-gene tumour-normal panel with a companion diagnostic claim for KRAS and NRAS wild-type colorectal cancer (cetuximab and panitumumab eligibility) and with tumour-profiling claims across solid tumours. The matched-normal design distinguishes inherited variants from tumour-acquired ones and reduces false positives. Tempus pairs the test with its multimodal database and trial-matching software, which is the company's commercial thesis: the test is the entry point to data.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2023 | Companion diagnostic for cetuximab and panitumumab (KRAS/NRAS wild-type colorectal cancer) with tumour-profiling claims |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- What a result means: a RAS mutation rules out EGFR antibodies in bowel cancer; other findings feed treatment and trial options.
Latest papers
topQuery for this drug: (TITLE:"Tempus xT CDx" OR ABSTRACT:"Tempus xT CDx" OR TITLE:"xT CDx" OR ABSTRACT:"xT CDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tempus xT CDx, not a curated reading list.
Pages like this
not linked directly; found by shared links- Producttherascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)
Shares Panitumumab, Cetuximab, Companion diagnostics, KRAS and the tag test.
- ProductMI Cancer Seek
Shares Next-generation sequencing (NGS), Companion diagnostics, Comprehensive genomic profiling, Colorectal cancer and the tag test.
- ProductOncomine Dx Target Test
Shares Next-generation sequencing (NGS), Companion diagnostics, EGFR, Comprehensive genomic profiling and the tag test.
- ProductTruSight Oncology Comprehensive
Shares Next-generation sequencing (NGS), Companion diagnostics, Comprehensive genomic profiling and the tag test.
- ProductGuardant360 CDx
Shares Companion diagnostics, KRAS, EGFR, Comprehensive genomic profiling and the tag test.
- ProductResolution ctDx FIRST
Shares Companion diagnostics, KRAS and the tag test.
- Productcobas EGFR Mutation Test v2
Shares Companion diagnostics, EGFR and the tag test.
- ProductBRACAnalysis CDx
Shares Germline vs somatic mutations, Companion diagnostics and the tag test.